

21 June 2023

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by **Firebrick Pharma Limited** (**Issuer** or **Company**) (**ASX:FRE**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Act**").

The Company has today issued 1,060,000 ordinary fully paid shares at an issue price of \$0.15 ("**Issued Shares**") under Tranche 2 of the Placement announced on 1 May 2023 and approved by members at the general meeting held on 20 June 2023.

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
 - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully

Stephen Buckley

Company Secretary

About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine® Nasal Spray (“Nasodine”) and owns numerous granted and pending patents, including a core patent family that covers the use of Nasodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of Nasodine for the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently undertaking two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com